Changes in Radiotherapeutic Management After Additional 68Ga-PSMA-11 PET/CT Imaging in Detail [n, (%)]
| RT after 68Ga-PSMA-11 PET/CT imaging | ||||||||
| Planned RT before 68Ga-PSMA-11 PET/CT imaging | RT prostate only | RT prostate and pLN | RT prostate, pLN and SIB | SBRT only | ADT | Other, individual RT concept | RT pLN and SIB | Systemic chemotherapy |
| RT prostate only | X | — | 4/62 (6.5%) | 2/62 (3.2%) | 1/62 (1.6%) | 1/62 (1.6%) | — | — |
| RT prostate and pLN | 15/62 (24.2%) | X | 8/62 (12.9%) | — | — | 1/62 (1.6%) | — | — |
| RT prostate, pLN, and SIB | — | 1/62 (1.6%) | X | 1/62 (1.6%) | 2/62 (3.2%) | 3/62 (4.8%) | — | — |
| SBRT only | — | — | — | X | — | 3/62 (4.8%) | 1/62 (1.6%) | 1/62 (1.6%) |
| ADT | — | — | — | 5/62 (8.1%) | X | 4/62 (6.5%) | 6/62 (9.7%) | — |
| Individual RT concept | — | — | — | — | — | X | 2/62 (3.2%) | — |
| BSC | — | — | — | 1/62 (1.6%) | — | — | — | — |
RT = radiotherapy; pLN = pelvic lymph nodes; SIB = simultaneous integrated boost; SBRT = stereotactic body radiotherapy, ADT = androgen deprivation therapy; BSC = best supportive care.